Literature DB >> 21617976

¹²³I-MIBG scintigraphy/SPECT versus ¹⁸F-FDG PET in paediatric neuroblastoma.

Henriette Ingrid Melzer1, Eva Coppenrath, Irene Schmid, Michael H Albert, Dietrich von Schweinitz, Coral Tudball, Peter Bartenstein, Thomas Pfluger.   

Abstract

PURPOSE: To analyse different uptake patterns in (123)I-MIBG scintigraphy/SPECT imaging and (18)F-FDG PET in paediatric neuroblastoma patients.
METHODS: We compared 23 (123)I-MIBG scintigraphy scans and 23 (18)F-FDG PET scans (mean interval 10 days) in 19 patients with a suspected neuroblastic tumour (16 neuroblastoma, 1 ganglioneuroblastoma, 1 ganglioneuroma and 1 opsomyoclonus syndrome). SPECT images of the abdomen or other tumour-affected regions were available in all patients. Indications for (18)F-FDG PET were a (123)I-MIBG-negative tumour, a discrepancy in (123)I-MIBG uptake compared to the morphological imaging or imaging results inconsistent with clinical findings. A lesion was found by (123)I-MIBG scintigraphy and/or (18)F-FDG PET and/or morphological imaging.
RESULTS: A total of 58 suspicious lesions (mean lesion diameter 3.8 cm) were evaluated and 18 were confirmed by histology and 40 by clinical follow-up. The sensitivities of (123)I-MIBG scintigraphy and (18)F-FDG PET were 50% and 78% and the specificities were 75% and 92%, respectively. False-positive results (three (123)I-MIBG scintigraphy, one (18)F-FDG PET) were due to physiological uptake or posttherapy changes. False-negative results (23 (123)I-MIBG scintigraphy, 10 (18)F-FDG PET) were due to low uptake and small lesion size. Combined (123)I-MIBG scintigraphy/(18)F-FDG PET imaging showed the highest sensitivity of 85%. In 34 lesions the (123)I-MIBG scintigraphy and morphological imaging findings were discrepant. (18)F-FDG PET correctly identified 32 of the discrepant findings. Two bone/bone marrow metastases were missed by (18)F-FDG PET.
CONCLUSION: (123)I-MIBG scintigraphy and (18)F-FDG PET showed noticeable differences in their uptake patterns. (18)F-FDG PET was more sensitive and specific for the detection of neuroblastoma lesions. Our findings suggest that a (18)F-FDG PET scan may be useful in the event of discrepant or inconclusive findings on (123)I-MIBG scintigraphy/SPECT and morphological imaging.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21617976     DOI: 10.1007/s00259-011-1843-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Guidelines for radioiodinated MIBG scintigraphy in children.

Authors:  Pierre Olivier; Paula Colarinha; Jure Fettich; Sibylle Fischer; Jörgen Frökier; Francesco Giammarile; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Amy Piepsz; Ute Porn; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-26       Impact factor: 9.236

2.  [Treatment results of children with neuroblastoma: report of Polish Pediatric Solid Tumor Group].

Authors:  Walentyna Balwierz; Aleksandra Wieczorek; Tomasz Klekawka; Katarzyna Garus; Katarzyna Bolek-Marzec; Danuta Perek; Ewa Swieszkowska; Wojciech Młynarski; Małgorzata Stolarska; Jerzy R Kowalczyk; Joanna Nurzyńska-Flak; Anna Balcerska; Ewa Bień; Jacek Wachowiak; Danuta Januszkiewicz-Lewandowska; Wojciech Woźniak; Anna Raciborska; Alicja Chybicka; Marek Ussowicz; Maryna Krawczuk-Rybak; Katarzyna Muszyńska-Rosłan; Mariusz Wysocki; Sylwia Kołtan; Grazyna Sobol; Agnieszka Mizia-Malarz; Tomasz Urasiński; Jarosław Peregut-Pogorzelski; Danuta Sońta-Jakimczyk; Halina Bubała; Maria Wieczorek; Michał Matysiak; Barbara Sopyło; Wojciech Madziara
Journal:  Przegl Lek       Date:  2010

3.  Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

Authors:  S G DuBois; Y Kalika; J N Lukens; G M Brodeur; R C Seeger; J B Atkinson; G M Haase; C T Black; C Perez; H Shimada; R Gerbing; D O Stram; K K Matthay
Journal:  J Pediatr Hematol Oncol       Date:  1999 May-Jun       Impact factor: 1.289

4.  Outcomes for children and adolescents with cancer: challenges for the twenty-first century.

Authors:  Malcolm A Smith; Nita L Seibel; Sean F Altekruse; Lynn A G Ries; Danielle L Melbert; Maura O'Leary; Franklin O Smith; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-04-19       Impact factor: 44.544

Review 5.  Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Authors:  K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 6.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Authors:  G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg
Journal:  J Clin Oncol       Date:  1993-08       Impact factor: 44.544

7.  Integrated imaging using MRI and 123I metaiodobenzylguanidine scintigraphy to improve sensitivity and specificity in the diagnosis of pediatric neuroblastoma.

Authors:  Thomas Pfluger; Christoph Schmied; Ute Porn; Gerda Leinsinger; Christian Vollmar; Stefan Dresel; Irene Schmid; Klaus Hahn
Journal:  AJR Am J Roentgenol       Date:  2003-10       Impact factor: 3.959

Review 8.  MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma.

Authors:  A Boubaker; A Bischof Delaloye
Journal:  Q J Nucl Med Mol Imaging       Date:  2008-12       Impact factor: 2.346

9.  Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.

Authors:  Brian H Kushner; Samuel D J Yeh; Kim Kramer; Steven M Larson; Nai-Kong V Cheung
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

10.  Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.

Authors:  B L Shulkin; R J Hutchinson; V P Castle; G A Yanik; B Shapiro; J C Sisson
Journal:  Radiology       Date:  1996-06       Impact factor: 11.105

View more
  24 in total

1.  Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study.

Authors:  Arnoldo Piccardo; Egesta Lopci; Massimo Conte; Alberto Garaventa; Luca Foppiani; Vania Altrinetti; Cristina Nanni; Pietro Bianchi; Angela Cistaro; Stefania Sorrentino; Manlio Cabria; Andrea Pession; Matteo Puntoni; Giampiero Villavecchia; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09-20       Impact factor: 9.236

2.  Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice.

Authors:  Carmelo Quarta; Erika Cantelli; Cristina Nanni; Valentina Ambrosini; Daniela D'ambrosio; Korinne Di Leo; Silvia Angelucci; Federico Zagni; Filippo Lodi; Mario Marengo; William A Weiss; Andrea Pession; Roberto Tonelli; Stefano Fanti
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

3.  Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.

Authors:  Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

4.  Guidelines on nuclear medicine imaging in neuroblastoma.

Authors:  Zvi Bar-Sever; Lorenzo Biassoni; Barry Shulkin; Grace Kong; Michael S Hofman; Egesta Lopci; Irina Manea; Jacek Koziorowski; Rita Castellani; Ariane Boubaker; Bieke Lambert; Thomas Pfluger; Helen Nadel; Susan Sharp; Francesco Giammarile
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10       Impact factor: 9.236

5.  Prognostic imaging of neuroblastoma.

Authors:  Anna-Liisa Brownell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06       Impact factor: 9.236

Review 6.  2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.

Authors:  John Freebody; Eva A Wegner; Monica A Rossleigh
Journal:  World J Radiol       Date:  2014-10-28

Review 7.  Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.

Authors:  Julie R Park; Rochelle Bagatell; Susan L Cohn; Andrew D Pearson; Judith G Villablanca; Frank Berthold; Susan Burchill; Ariane Boubaker; Kieran McHugh; Jed G Nuchtern; Wendy B London; Nita L Seibel; O Wolf Lindwasser; John M Maris; Penelope Brock; Gudrun Schleiermacher; Ruth Ladenstein; Katherine K Matthay; Dominique Valteau-Couanet
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

Review 8.  [Simultaneous whole-body PET-MRI in pediatric oncology : More than just reducing radiation?].

Authors:  S Gatidis; B Gückel; C la Fougère; J Schmitt; J F Schäfer
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

9.  Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

Authors:  Hanwen Zhang; Ruimin Huang; Nai-Kong V Cheung; Hongfen Guo; Pat B Zanzonico; Howard T Thaler; Jason S Lewis; Ronald G Blasberg
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

Review 10.  Nuclear medicine and multimodality imaging of pediatric neuroblastoma.

Authors:  Wolfgang Peter Mueller; Eva Coppenrath; Thomas Pfluger
Journal:  Pediatr Radiol       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.